{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.5"}]}],"title":"ACR20 Week 24 (n=1966)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7"}]}],"title":"ACR20 Week 48 (n=1825)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.1"}]}],"title":"ACR20 Week 108 (n=1607)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.3"}]}],"title":"ACR20 Week 156 (n=1512)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.5"}]}],"title":"ACR20 Week 204 (n=1415)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"78.7"}]}],"title":"ACR20 Week 264 (n = 1319)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.9"}]}],"title":"ACR50 Week 24 (n=1966)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4"}]}],"title":"ACR50 Week 48 (n=1825)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.8"}]}],"title":"ACR50 Week 108 (n=1607)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.7"}]}],"title":"ACR50 Week 156 (n=1512)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.5"}]}],"title":"ACR50 Week 204 (n=1415)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.8"}]}],"title":"ACR50 Week 264 (n= 1319)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8"}]}],"title":"ACR70 Week 24 (n=1966)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5"}]}],"title":"ACR70 Week 48 (n=1825)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.2"}]}],"title":"ACR70 Week 108 (n=1607)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7"}]}],"title":"ACR70 Week 156 (n=1512)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6"}]}],"title":"ACR70 Week 204 (n =1415)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40.5"}]}],"title":"ACR70 Week 264 (n=1319)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"}]}],"title":"ACR90 Week 24 (n=1966)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9"}]}],"title":"ACR90 Week 48 (n=1825"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1"}]}],"title":"ACR90 Week 108 (n=1607)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7"}]}],"title":"ACR90 Week 156 (n=1512)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7"}]}],"title":"ACR90 Week 204 (n=1415)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1"}]}],"title":"ACR90 Week 264 (n=1319)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"Improvement must be seen in tender (68 assessed joints) and swollen joint counts (66 assessed joints) and in at least 3 of the following 5 parameters: Separate patient and physician assessments of patient disease activity in the previous 24 hours on a visual analog scale (VAS, the left end of the scale \"no disease activity\" \\[symptom-free and no arthritis symptoms\\], right end of the scale \"maximum disease activity\"); patient assessment of pain in the previous 24 hours on a VAS (left end of the scale \"no pain\", right end of the scale \"unbearable pain\"); Health Assessment Questionnaire-Disability Index (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do); and erythrocyte sedimentation rate.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Percentage of Participants With an Improvement of at Least 20%, 50%, 70%, or 90% in the American College of Rheumatology (ACR) Score (ACR20/50/70/90) From Baseline at Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}